Completed PHASE3 INTERVENTIONAL NCT00196924

Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.

Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to a 0,1,6 Month Schedule in Healthy Female Subjects (10 - 14 Years)

Sponsor: GlaxoSmithKline

Conditions Infections, Papillomavirus

Interventions HPV-16/18 L1/AS04

Updated 6 times since 2017 Last updated: Mar 21, 2017 Started: Jun 30, 2004 Primary completion: Mar 31, 2006 Completion: Mar 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Infections, Papillomavirus, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 6 data snapshots since 2004. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alcora/Castellón, Spain , Alquerías Del Niño Perdido (Castellón), Spain , Aubevoye, France , Barcelona, Spain , Bergen, Norway , Berlin, Germany , Bochum, Germany , Bogotá, Colombia , Bredstedt, Germany , Broglie, France and 45 more locations